-
1
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort studyResearch in contex...
Published 2023-01-01“…Summary: Background: Recognising the importance of clinical outcomes assessments (COAs), the Response Assessment in Neuro-Oncology-Patient Reported Outcome (RANO-PRO) Working Group recommended inclusion of core symptoms and functions in clinical care or research for malignant glioma patients. …”
Get full text
Article -
2
-
3
-
4
Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by Isovalerylspiramycin I
Published 2022-04-01Get full text
Article -
5
-
6
Endogenous Retroviral Elements in Human Development and Central Nervous System Embryonal Tumors
Published 2021-12-01Get full text
Article -
7
-
8
-
9
-
10
-
11
-
12
-
13
Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival
Published 2021-06-01Get full text
Article -
14
Clinical outcome assessment trends in clinical trials—Contrasting oncology and non‐oncology trials
Published 2023-08-01Get full text
Article -
15
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
Published 2020-06-01Get full text
Article -
16
Sphingolipid Pathway as a Source of Vulnerability in IDH1<i><sup>mut</sup></i> Glioma
Published 2020-10-01Get full text
Article -
17
A Transgenic Mouse Model of Pacak–Zhuang Syndrome with An <i>Epas1</i> Gain-of-Function Mutation
Published 2019-05-01Get full text
Article -
18
Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma
Published 2020-01-01Get full text
Article -
19
Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
Published 2021-12-01Get full text
Article